Dr. Rohit Bhatheja, MD

Medicare patients and services

Medicare patients, 2024

1,887

Services billed

5,663

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 24 companies reported 92 payments worth $29,363 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $78,493 in research payments for these studies, mostly to the institutions running them.

• A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
  Amgen Inc.
• A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
  Novartis Pharmaceuticals Corporation
• STRIKE-PE
  Penumbra, Inc.
• Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial
  Abbott Laboratories · Active, not recruiting · NCT03108456
• A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly…
  Amgen Inc.
• NCT06707688--Abbott Medical - VERITAS Study
  Abbott Laboratories
• NCT03507777--ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)
  Abbott Laboratories

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Cardiology clinicians in Orlando

• Syed Z. Abbas, MD
• Ali S. Abbood, MD
• Saurabh Aggarwal, MD
• Saba Ahmad, M.D.
• Kamran Akram, MD
• Lucianne Alers Sanchez, MD
• Mahmoud Altawil, MD
• George E. Andreae, MD